Regenxbio Inc Dossier - Source-backed chat

Regenxbio Inc

RGNXNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.96

Intrinsic Value

No headline value published yetWe haven't published a headline intrinsic value for this company yet. Our data-reliability standards weren't met. Method estimates are shown for reference.

Market Price $7.42Price as of 1 Oct 2026

Data confidence Sign in to view data confidence

Market Cap $489.8M

Enterprise Value $616.4M

Shares Outstanding 66M diluted

Next Earnings Date5 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

REGENXBIO is a clinical-stage biotechnology company pioneering adeno-associated virus (AAV) gene therapies. The company's investment profile is highly bifurcated. On one hand, it recently achieved a major clinical milestone with positive topline Phase III results for RGX-202 in Duchenne Muscular Dystrophy (DMD), demonstrating a statistically significant correlation between microdystrophin expression and functional improvement. On the other hand, the company faces severe regulatory and financial headwinds, including a Complete Response Letter (CRL) from the FDA in February 2026 rejecting its BLA for RGX-121 (Hunter syndrome), clinical holds on its MPS programs, and a rapidly depleting cash runway (funding operations only into early 2027). While a pending $100 million milestone from AbbVie and potential accelerated approval of RGX-202 offer upside, the high cash burn and regulatory uncertainty warrant a cautious Hold stance.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets11 analysts · as of 18 Aug 2026

Low · most bearish analyst$10.00

Mean target$24.27

High · most bullish analyst$50.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The bear case is driven by prolonged regulatory delays and financing risk. The FDA demands a new, randomized controlled trial for RGX-121, effectively shelving the program due to the challenges of recruiting ultra-rare disease patients. Furthermore, the FDA raises unexpected hurdles during the pre-BLA meeting for RGX-202, delaying its submission. With a high cash burn rate ($90.1 million net loss in Q1 2026) and only $150.5 million in cash as of March 31, 2026, any delay in the AbbVie milestone or clinical timelines forces highly dilutive equity financing, severely depressing the stock price.

Base CaseCentral scenario

The base case assumes REGENXBIO successfully files a BLA for RGX-202 under the accelerated approval pathway by late 2026 or early 2027, leveraging its strong Phase III microdystrophin correlation data. It also assumes the company receives the $100 million milestone payment from AbbVie in mid-2026, extending its cash runway through 2027. However, the MPS programs (RGX-121 and RGX-111) remain delayed as the company negotiates complex clinical trial designs and addresses safety holds with the FDA, keeping near-term commercialization of those assets out of reach.

Bull CaseUpside scenario

The bull case for REGENXBIO centers on its transition to a multi-catalyst late-stage gene therapy platform. Key pillars include: 1) The potential accelerated FDA approval of RGX-202 for Duchenne Muscular Dystrophy (DMD) by 2027, supported by positive Phase III AFFINITY DUCHENNE data; 2) The partnered retinal program with AbbVie for ABBV-RGX-314 (sura-vec) in wet AMD, with pivotal topline data expected in Q4 2026 and a potential $100 million milestone payment; and 3) A planned Q3 2026 BLA resubmission path for NAVSUNLI (RGX-121) in Hunter syndrome following alignment with the FDA.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong Phase III data for RGX-202 in DMD, showing a statistically significant correlation between microdystrophin expression and functional improvement (NSAA), which supports a robust path to accelerated approval.
High-value strategic collaboration with AbbVie for sura-vec (ABBV-RGX-314) in wet AMD and diabetic retinopathy, which provides substantial non-dilutive funding, including an expected $100 million milestone payment.
Proprietary NAV Technology Platform with deep AAV vector expertise and state-of-the-art in-house manufacturing capabilities (NAVXpress) in Rockville, MD.

Key Investment Risks

Severely limited cash runway, with existing cash of $150.5 million as of March 31, 2026, expected to fund operations only into early 2027, creating high dilution risk if milestones are delayed.
Significant regulatory setbacks, highlighted by the February 2026 FDA Complete Response Letter (CRL) rejecting RGX-121 due to concerns over trial design, external controls, and surrogate endpoints.
Clinical holds on both RGX-121 and RGX-111 following a serious adverse event (brain tumor) in a patient treated with RGX-111, raising safety and platform-integration concerns.

Thesis Invalidation Triggers

Failure to secure the $100 million milestone payment from AbbVie in 2026, which would trigger an immediate liquidity crisis.
An unfavorable pre-BLA meeting with the FDA for RGX-202 where regulators reject microdystrophin expression as a surrogate endpoint or demand a randomized controlled trial.
Definitive evidence linking the AAV vector integration to the brain tumor observed in the RGX-111 trial, which would compromise the safety profile of the entire NAV platform.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.